Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Ikena Oncology (IKNA)
NASDAQ:IKNA
Ikena Oncology (IKNA) Stock Price & Analysis
96 Followers
IKNA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.02 - $7.38
Previous Close$1.43
Volume154.58K
Average Volume (3M)346.66K
Market Cap
$69.01M
Enterprise Value-$94.77M
Total Cash (Recent Filing)$175.47M
Total Debt (Recent Filing)$11.69M
Price to Earnings (P/E)-0.9
Beta0.95
Next Earnings
Aug 08, 2024EPS Estimate
-$0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.58
Shares Outstanding48,258,111
10 Day Avg. Volume202,821
30 Day Avg. Volume346,660
Standard Deviation0.26
R-Squared0.00435
Alpha-0.05
Financial Highlights & Ratios
Price to Book (P/B)0.41
Price to Sales (P/S)7.53
Price to Cash Flow (P/CF)-0.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-10.35
Enterprise Value/Gross Profit-10.35
Enterprise Value/Ebitda2.71
Forecast
1Y Price Target
$9.50Price Target Upside578.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Ikena Oncology News
Bulls Say, Bears Say
Bulls Say
Clinical AdvancementsIkena's pipeline provides optionality including RAS/RAF for IK-595, with a clinical update expected in the second half of the year showcasing potential advancements in oncology treatments.
Financial StabilityIkena has a strong financial position with sufficient cash through the second half of the year, allowing for continuous development and potential market re-engagement based on upcoming program updates.
Innovation And Market PotentialAnalyst reiterates a Buy rating and a price target, highlighting the potential for Ikena's innovative oncology assets, like IK-930, to demonstrate increased exposure levels and a favorable pharmacokinetic/pharmacodynamic profile.
Bears Say
Clinical Trial ResultsInitial IK-930 Ph1 Data Is Disappointing, with no response observed in 7 EHE patients during the dose-escalation phase.
Drug EfficacyUpon release of the data, IMRX stock fell stemming from a lack of efficacy at the RP2D dose level, bringing into question IMM-1-104’s mechanistic rationale.
Drug SafetyTwo EHE patients experienced Grade 3-4 liver enzyme elevation, one deemed dose limiting.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
IKNA FAQ
What was Ikena Oncology’s price range in the past 12 months?
Ikena Oncology lowest stock price was $1.02 and its highest was $7.38 in the past 12 months.
What is Ikena Oncology’s market cap?
Currently, no data Available
When is Ikena Oncology’s upcoming earnings report date?
Ikena Oncology’s upcoming earnings report date is Aug 08, 2024 which is in 79 days.
How were Ikena Oncology’s earnings last quarter?
Ikena Oncology released its earnings results on May 13, 2024. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.398 by $0.068.
Is Ikena Oncology overvalued?
According to Wall Street analysts Ikena Oncology’s price is currently Undervalued.
Does Ikena Oncology pay dividends?
Ikena Oncology does not currently pay dividends.
What is Ikena Oncology’s EPS estimate?
Ikena Oncology’s EPS estimate is -$0.34.
How many shares outstanding does Ikena Oncology have?
Ikena Oncology has 48,258,110 shares outstanding.
What happened to Ikena Oncology’s price movement after its last earnings report?
Ikena Oncology reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.398. Following the earnings report the stock price went up 0.758%.
Which hedge fund is a major shareholder of Ikena Oncology?
Among the largest hedge funds holding Ikena Oncology’s share is Omega Fund Management, LLC. It holds Ikena Oncology’s shares valued at 3M.
---
Ikena Oncology Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$9.50 (578.57% Upside)
$9.50 (578.57% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 7.8%
Last 30 Days ▼ 7.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-77.93%
12-Months-Change
Fundamentals
Return on Equity
-48.28%
Trailing 12-Months
Asset Growth
13.37%
Trailing 12-Months
Company Description
Ikena Oncology
Ikena Oncology Inc is an oncology company. It is focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. The company is advancing five clinical, preclinical and discovery programs: IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; IK-412, a kynurenine-degrading enzyme Kynase; discovery-stage molecules targeting the Hippo signaling pathway; and a discovery-stage program against an undisclosed target.
---
IKNA Stock 12 Month Forecast
Average Price Target
$9.50
▲(578.57% Upside)
Technical Analysis
Best Analysts Covering IKNA
1 Year
1 Year Success Rate
2/5 ratings generated profit
1 Year Average Return
-28.62%
reiterated a buy rating 2 months ago
Copying Andres Y. Maldonado's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of -28.62% per trade.
---